---
title: "港股藥品股午後下挫，康龍化成跌超 11%，兆科眼科跌超 9%，復星醫藥、中國生物製藥等跟跌。"
description: "港股藥品股午後下挫，康龍化成跌超 11%，兆科眼科跌超 9%，復星醫藥、中國生物製藥等跟跌。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/107281095.md"
published_at: "2024-02-02T05:08:38.000Z"
---

# 港股藥品股午後下挫，康龍化成跌超 11%，兆科眼科跌超 9%，復星醫藥、中國生物製藥等跟跌。

港股藥品股午後下挫，康龍化成 (03759.HK) 跌超 11%，兆科眼科 (06622.HK) 跌超 9%，復星醫藥 (02196.HK)、中國生物製藥 (01177.HK) 等跟跌。

### Related Stocks

- [600196.CN - 復星醫藥](https://longbridge.com/zh-HK/quote/600196.CN.md)
- [02196.HK - 復星醫藥](https://longbridge.com/zh-HK/quote/02196.HK.md)
- [00656.HK - 復星國際](https://longbridge.com/zh-HK/quote/00656.HK.md)
- [06622.HK - 兆科眼科-B](https://longbridge.com/zh-HK/quote/06622.HK.md)
- [01177.HK - 中國生物制藥](https://longbridge.com/zh-HK/quote/01177.HK.md)
- [300759.CN - 康龍化成](https://longbridge.com/zh-HK/quote/300759.CN.md)
- [03759.HK - 康龍化成](https://longbridge.com/zh-HK/quote/03759.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Shanghai Fosun Pharmaceutical erhält Annahme für Arzneimittelzulassungsantrag | Shanghai Fosun Pharmaceutical (Group) Co. Ltd. announced that a subsidiary's drug approval application has been accepted | [Link](https://longbridge.com/zh-HK/news/275434480.md) |
| Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application | Fosun Pharma Unit Gets China Acceptance for Anesthesia Drug Application | [Link](https://longbridge.com/zh-HK/news/275893661.md) |
| IStyle Takes High-Rent Hong Kong Bet With First Overseas Flagship | IStyle Takes High-Rent Hong Kong Bet With First Overseas Flagship | [Link](https://longbridge.com/zh-HK/news/275675822.md) |
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/zh-HK/news/276024005.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/zh-HK/news/276016059.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。